Basit öğe kaydını göster

Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC

dc.contributor.authorJassem, Jacek
dc.contributor.authorKomatsubara, Kimberly
dc.contributor.authorDeng, Yu
dc.contributor.authorKuriki, Hiroshi
dc.contributor.authorWen, Xiaohui
dc.contributor.authorMcCleland, Mark
dc.contributor.authorMocci, Simonetta
dc.contributor.authorHerbst, Roy S.
dc.contributor.authorSpigel, David R.
dc.contributor.authorGiaccone, Giuseppe
dc.contributor.authorde Marinis, Filippo
dc.contributor.authorReinmuth, Niels
dc.contributor.authorVergnenegre, Alain
dc.contributor.authorBarrios, Carlos H.
dc.contributor.authorMorise, Masahiro
dc.contributor.authorFelip, Enriqueta
dc.contributor.authorAndric, Zoran
dc.contributor.authorGeater, Sarayut
dc.contributor.authorÖZGÜROĞLU, Mustafa
dc.contributor.authorZou, Wei
dc.contributor.authorSandler, Alan
dc.contributor.authorEnquist, Ida
dc.date.accessioned2021-03-02T16:34:41Z
dc.date.available2021-03-02T16:34:41Z
dc.date.issued2020
dc.identifier.citationHerbst R. S. , Giaccone G., de Marinis F., Reinmuth N., Vergnenegre A., Barrios C. H. , Morise M., Felip E., Andric Z., Geater S., et al., "Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC", NEW ENGLAND JOURNAL OF MEDICINE, cilt.383, sa.14, ss.1328-1339, 2020
dc.identifier.issn0028-4793
dc.identifier.otherav_28702e94-ce8a-4ced-9a40-d3b62ca05652
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/3223
dc.identifier.urihttps://doi.org/10.1056/nejmoa1917346
dc.description.abstractBackgroundThe efficacy and safety of the anti-programmed death ligand 1 (PD-L1) monoclonal antibody atezolizumab, as compared with those of platinum-based chemotherapy, as first-line treatment for patients with metastatic non-small-cell lung cancer (NSCLC) with PD-L1 expression are not known.
dc.language.isoeng
dc.subjectTIP, GENEL & İÇECEK
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectTemel Tıp Bilimleri
dc.titleAtezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC
dc.typeMakale
dc.relation.journalNEW ENGLAND JOURNAL OF MEDICINE
dc.contributor.departmentYale University , ,
dc.identifier.volume383
dc.identifier.issue14
dc.identifier.startpage1328
dc.identifier.endpage1339
dc.contributor.firstauthorID2287924


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster